



Fax

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

Date: May 12, 2004

To: Examiner Hope Robinson
Company: USPTO:1600 Technology Ctr.
Fax: 571-273-0957
Fax: 703-872-9306

From: Greg Cox
Fax: 317-276-5172
Phone: 317-277-2620
Total Pages: 9

RECEIVED
CENTRAL FAX CENTER

MAY 12 2004



Privileged and Confidential Communication

Subject: Response and Amendment for 09/868974
Art Unit: 1653
Lilly Reference Docket No. X-11869

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

MAY 12 2004

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

JANET FOWLER

Type or print name of person signing certification

Janet Fowler

Signature

5/12/04

Date

OFFICIAL

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Mark L. Brader, et al.)	
)	
Serial No.	:	09/868,974)	
)	Group Art Unit:
Filed	:	December 21, 1999)	1653
)	
For	:	Shelf-Stable Formulation of)	Examiner:
		Glucagon-Like Peptide-1)	H. Robinson
)	
Docket No.	:	X-11869)	

Response and Amendment Under 37 C.F.R. §1.111 and 37 C.F.R. §1.121

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

This paper is filed in response to the Examiner's rejection of Claims 27-36, 40-43, and 47. Please cancel Claims 31, 32, 38, 39, 45, and 46. Claims 27-31, 33-37, 40-44 and 47 are currently pending in the Application. Applicants respectfully request that the Examiner enter the following amendments that Applicants believe place the application in condition for allowance.

No Amendments to the Claims have been submitted. The pending claims are reproduced for the Examiner's convenience. The listing of claims begins on page 2 of this paper.

Remarks and Arguments begins on page 5 of this paper.

Summary and Conclusion begins on page 8 of this paper.